A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Investigate Safety and Efficacy of Tibolone (Org OD14) in Women With Climacteric Symptoms and a History of Breast Cancer

Trial Profile

A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Investigate Safety and Efficacy of Tibolone (Org OD14) in Women With Climacteric Symptoms and a History of Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Tibolone (Primary)
  • Indications Vasomotor symptoms
  • Focus Therapeutic Use
  • Acronyms LIBERATE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Jun 2011 QOL results presented at the 13th World Congress on Menopause.
    • 13 Oct 2009 Additional trial sponsor (Schering-Plough) added as reported by ClinicalTrials.gov.
    • 10 Dec 2008 Results from a bone substudy were presented at the 31st Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top